TransMedics Group, Inc.
TMDX
$121.31
-$7.66-5.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.13% | 41.20% | 48.09% | 64.43% | 82.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.13% | 41.20% | 48.09% | 64.43% | 82.74% |
| Cost of Revenue | 35.23% | 37.92% | 51.56% | 77.26% | 105.03% |
| Gross Profit | 38.43% | 43.45% | 45.85% | 56.70% | 70.08% |
| SG&A Expenses | 9.82% | 17.09% | 24.60% | 36.78% | 43.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.98% | 27.95% | 37.65% | 54.55% | 67.56% |
| Operating Income | 189.59% | 186.82% | 169.55% | 250.24% | 7,631.13% |
| Income Before Tax | 200.51% | 184.43% | 4,906.22% | 529.61% | 234.15% |
| Income Tax Expenses | -26,292.72% | 6,856.25% | 259.87% | 176.41% | 119.23% |
| Earnings from Continuing Operations | 436.58% | 181.16% | 2,288.73% | 580.13% | 241.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 436.58% | 181.16% | 2,288.73% | 580.13% | 241.70% |
| EBIT | 189.59% | 186.82% | 169.55% | 250.24% | 7,631.13% |
| EBITDA | 134.86% | 135.74% | 134.31% | 183.01% | 560.98% |
| EPS Basic | 421.46% | 173.50% | 2,410.18% | 564.23% | 239.32% |
| Normalized Basic EPS | 193.08% | 160.64% | 134.92% | 178.26% | 1,306.25% |
| EPS Diluted | 376.19% | 165.89% | 5,763.75% | 494.65% | 230.87% |
| Normalized Diluted EPS | 160.40% | 134.23% | 112.95% | 162.11% | 1,385.08% |
| Average Basic Shares Outstanding | 2.30% | 2.56% | 2.69% | 2.54% | 2.19% |
| Average Diluted Shares Outstanding | 15.11% | 11.87% | 10.68% | 9.01% | 7.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |